What are the first‑line medication choices, dosing regimens, and contraindications for treating ADHD in children (6‑12 years), adolescents, and adults?

ADHD Medication: First-Line Choices, Dosing, and Contraindications

First-Line Medication Recommendations by Age Group

For children aged 6-12 years, prescribe FDA-approved stimulant medications—specifically methylphenidate or amphetamines—as first-line pharmacological treatment, preferably combined with behavioral interventions. 1

Children (6-11 years)

• Stimulants are the strongest evidence-based choice with effect sizes of approximately 1.0 1
• Methylphenidate is recommended as initial therapy based on the strongest evidence 1
• Amphetamines are equally effective alternatives
• Non-stimulants (atomoxetine, extended-release guanfacine, extended-release clonidine) have weaker evidence (effect size ~0.7) and should be considered second-line 1

Adolescents (12-18 years)

• FDA-approved stimulant medications with adolescent assent 1, 2
• Same medication hierarchy as children: stimulants first-line, non-stimulants second-line
• Behavioral therapy may be added but has weaker evidence in this age group 1

Adults

• Amphetamines are the preferred first-choice medication based on superior efficacy data 3
• Methylphenidate is an effective alternative
• Atomoxetine and bupropion show moderate efficacy (effect size -0.45 to -0.46) 3

Preschool Children (4-5 years)

• Behavioral therapy (parent/teacher-administered) is mandatory first-line treatment 1
• Methylphenidate may be prescribed only if behavioral interventions fail AND there is moderate-to-severe functional impairment 4
• No non-stimulant medications have adequate evidence in this age group 4

Dosing Regimens

Methylphenidate

Starting dose: 5 mg twice daily (morning after breakfast, noon after lunch) 5

Titration schedule:

• Increase by 5-10 mg per dose weekly based on response 5
• Flexible titration to higher doses improves both efficacy and acceptability 6
• Maximum benefit typically achieved at 30 mg/day in fixed-dose trials, but flexible dosing shows continued benefit across FDA-licensed range 6

Maximum doses:

• PDR recommends 60 mg/day total 5
• Expert consensus: up to 25 mg single dose when given multiple times daily 5
• Children <25 kg: generally should not exceed 15 mg single dose 5

Amphetamines (Dextroamphetamine/Mixed Salts)

Starting dose: 2.5 mg twice daily 5

Titration schedule:

• Increase by 2.5-5 mg per dose weekly 5

Maximum doses:

• PDR recommends 40 mg/day total 5
• Expert consensus: up to 40 mg/day total 5
• Children <25 kg: generally should not exceed 10 mg single dose 5

Atomoxetine

Dosing approach: Weight-based sequential titration 7

Maximum dose: 1.4 mg/kg/day or 100 mg/day, whichever is lower 7

Important consideration: Metabolized via CYP2D6—approximately 7% of patients are poor metabolizers with significantly higher plasma levels and increased adverse effects 7

Extended-Release Guanfacine and Clonidine

• Used as monotherapy or adjunctive therapy with stimulants 1, 4
• Must be tapered when discontinuing to avoid rebound hypertension 4

Critical Contraindications

Absolute Contraindications for Stimulants

• Previous hypersensitivity to stimulant medications 5
• Glaucoma 5
• Symptomatic cardiovascular disease 5
• Hyperthyroidism 5
• Hypertension 5
• Concomitant MAO inhibitor use 5
• Active psychotic disorder 5
• History of illicit stimulant use/abuse (unless controlled setting with close supervision) 5

Relative Contraindications (Require Careful Consideration)

• Motor tics and Tourette's disorder: FDA package inserts list as contraindications, but recent clinical trials suggest these conditions may not worsen with stimulant treatment 5
• Marked anxiety: Listed in FDA inserts but clinical evidence is mixed 5
• Seizure disorders: Best to initiate after seizure control achieved with anticonvulsants; published studies show no change in seizure frequency when methylphenidate added 5

Atomoxetine-Specific Warnings

• Black box warning for suicidal ideation in children and adolescents (not observed in adults) 7
• Monitor closely for suicidality, clinical worsening, unusual behavioral changes, especially during first months or dose changes 7
• Preexisting cardiovascular disease/cardiac abnormalities 7
• Bipolar disorder, psychotic symptoms, aggressive behavior 7
• Extremely rare: hepatitis 4

Alpha-2 Agonists (Guanfacine/Clonidine) Warnings

• Somnolence, bradycardia, hypotension 4
• Rebound hypertension with abrupt discontinuation—must taper 4

Monitoring Requirements

Pre-Treatment Assessment

• Physical examination including: blood pressure, pulse, height, weight 5
• Cardiac history: Wolf-Parkinson-White syndrome, sudden death in family, hypertrophic cardiomyopathy, long QT syndrome 1

Ongoing Monitoring

• Children: Vital signs checked annually during routine physical 5
• Adults on stimulants: Blood pressure and pulse quarterly 5
• Weight at each visit to objectively assess appetite suppression 5
• Systematic assessment of side effects: insomnia, anorexia, headaches, social withdrawal, tics, weight loss 5

Titration Phase

• Weekly contact (may be by telephone) during dose adjustments 5
• Typically requires 2-4 weeks 5

Maintenance Phase

• At least monthly appointments until symptoms stabilized 5
• More frequent if side effects, comorbidities, or adherence concerns 5
• Obtain teacher reports regularly 5

Common Adverse Effects

Stimulants

• Appetite loss, abdominal pain, headaches, sleep disturbance 1
• Growth velocity reduction (1-2 cm range, diminishes by third year) 1
• Uncommon: hallucinations and psychotic symptoms 1
• Preschool children: increased mood lability and dysphoria 1

Atomoxetine

• Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 7
• Initial somnolence and GI symptoms (worse with rapid titration) 1

Extended-Release Guanfacine/Clonidine

• Somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, abdominal pain 4

Key Clinical Pearls

Titrate to maximum benefit with minimum adverse effects rather than stopping at arbitrary dose limits 1. The evidence strongly supports flexible dosing strategies that allow individualized optimization based on symptom control and tolerability 6.

Stimulants remain underdosed in clinical practice 6. Don't hesitate to increase doses within FDA-approved ranges if symptoms persist and medication is well-tolerated.

Periodic reassessment is essential, potentially including medication-free intervals, to determine continued need for treatment 7.

For tolerability issues with stimulants: Consider extended-release guanfacine or clonidine as adjunctive therapy (FDA-approved for this indication) 1, 4.